Boston Scientific's Q1 Earnings Call: Our Top 5 Analyst Questions
Boston Scientific's first quarter results were met with a positive market reaction following revenue and profit that surpassed Wall Street expectations. Management credited robust growth in its cardiology portfolio and the successful execution of a category leadership strategy spanning electrophysiology, WATCHMAN, and interventional cardiology products. CEO Michael Mahoney highlighted that double-digit expansion in the U.S. and momentum in Europe and Japan helped drive operational sales growth, while new product launches and increased adoption in emerging segments, such as FARAPULSE and Axios, also contributed to performance.
Is now the time to buy BSX? Find out in our full research report (it's free).
Revenue: $4.66 billion vs analyst estimates of $4.57 billion (20.9% year-on-year growth, 2% beat)
Adjusted EPS: $0.75 vs analyst estimates of $0.67 (11.5% beat)
Revenue Guidance for Q2 CY2025 is $4.88 billion at the midpoint, above analyst estimates of $4.79 billion
Management raised its full-year Adjusted EPS guidance to $2.91 at the midpoint, a 2.5% increase
Operating Margin: 19.8%, up from 17.5% in the same quarter last year
Organic Revenue rose 18.2% year on year (13.1% in the same quarter last year)
Market Capitalization: $150.5 billion
While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Robert Marcus (JPMorgan) asked about mitigating tariff headwinds. CFO Daniel Brennan explained the offset through increased revenue and targeted cost reductions, with no plans for major manufacturing shifts.
Larry Biegelsen (Wells Fargo) questioned global electrophysiology market share. CEO Michael Mahoney acknowledged strong momentum and the goal of reaching #1, particularly through investments in China and Japan.
Joanne Wuensch (Citi) inquired about WATCHMAN's growth and procedural trends. Mahoney and Dr. Ken Stein cited rapid adoption of concomitant procedures and favorable clinical data as key drivers.
Travis Steed (Bank of America) asked about margin sustainability. Brennan attributed margin expansion to product mix and noted that tariffs will pressure gross margin in the second half, but full-year expansion is still expected.
Danielle Antalffy (UBS) raised questions on the SoniVie acquisition's timing and potential. Mahoney described the clinical trial process and anticipated a multi-year path to realizing commercial contributions.
In upcoming quarters, the StockStory team will monitor (1) continued growth and market share gains in electrophysiology and WATCHMAN, (2) progress on integrating new acquisitions and the resulting product launches, and (3) the company's ability to offset tariff-related cost pressures without sacrificing margin targets. Updates on key clinical trials and regulatory milestones will also be critical to tracking Boston Scientific's strategy execution.
Boston Scientific currently trades at $101.38, up from $94.97 just before the earnings. At this price, is it a buy or sell? See for yourself in our full research report (it's free).
The market surged in 2024 and reached record highs after Donald Trump's presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025.
While the crowd speculates what might happen next, we're homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver's seat and build a durable portfolio by checking out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Do You Believe in the Growth Trajectory of Boston Scientific Corporation (BSX)?
Parnassus Investments, an investment management company, released the 'Parnassus Growth Equity Fund' first quarter 2025 investor letter. A copy of the letter can be downloaded here. In the first quarter, the Fund (Investor Shares) returned -8.59% (net of fees), outperforming the Russell 1000 Growth Index's -9.97% decline. In the first quarter, post-election optimism, driven by reduced regulation and a business-friendly environment, drifted away to concerns over fiscal and tariff uncertainties, which increased volatility and raised fears of a recession. In addition, please check the fund's top five holdings to know its best picks in 2025. In its first-quarter 2025 investor letter, Parnassus Growth Equity Fund highlighted stocks such as Boston Scientific Corporation (NYSE:BSX). Boston Scientific Corporation (NYSE:BSX) manufactures and markets medical devices for use in various interventional medical specialties. The one-month return of Boston Scientific Corporation (NYSE:BSX) was -0.65%, and its shares gained 35.80% of their value over the last 52 weeks. On June 26, 2025, Boston Scientific Corporation (NYSE:BSX) stock closed at $104.58 per share with a market capitalization of $154.721 billion. Parnassus Growth Equity Fund stated the following regarding Boston Scientific Corporation (NYSE:BSX) in its Q1 2025 investor letter: "Boston Scientific Corporation (NYSE:BSX), a medical device company, continued to report exceptionally strong growth led by its existing Watchman heart implant franchise and its recently launched Farapulse franchise. We expect the company's robust growth trajectory to continue in upcoming years, given the potential market for Farapulse, a promising treatment for atrial fibrillation." A surgeon examining a patient's brain in an operating room, paramedics nearby. Boston Scientific Corporation (NYSE:BSX) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 108 hedge fund portfolios held Boston Scientific Corporation (NYSE:BSX) at the end of the first quarter, which was 96 in the previous quarter. Boston Scientific Corporation's (NYSE:BSX) reported revenue of $4.663 billion, reflecting a 20.9% growth compared to Q1 2024. While we acknowledge the potential of Boston Scientific Corporation (NYSE:BSX) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the undervalued AI stock set for massive gains. In another article, we covered Boston Scientific Corporation (NYSE:BSX) and shared the list of best stocks to invest in for a month. Boston Scientific Corporation (NYSE:BSX) contributed to Baron Health Care Fund's performance during Q1 2025. In addition, please check out our hedge fund investor letters Q1 2025 page for more investor letters from hedge funds and other leading investors. While we acknowledge the potential of BSX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Nevada reports May statewide gaming win down 2.18% to $1.29B
Nevada reports May Las Vegas Strip gaming win down 3.87% versus last year to $713.77M. Publicly traded companies in the gaming space include Boyd Gaming (BYD), Caesars (CZR), Churchill Downs (CHDN), DraftKings (DKNG), Flutter Entertainment (FLUT), Gan Limited (GAN), Genius Sports (GENI), Las Vegas Sands (LVS), MGM Resorts (MGM), Penn Entertainment (PENN), Rush Street Interactive (RSI), Sportradar (SRAD) and Wynn Resorts (WYNN). Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders' Hot Stocks on TipRanks >> Read More on BYD: Disclaimer & DisclosureReport an Issue NJ state budget proposes tax hike on online betting, reports Boyd Gaming initiated with a Neutral at JPMorgan International Game signs three-year sports betting pact with Boyd Gaming Boyd Gaming price target raised to $76 from $71 at Stifel Boyd Gaming COO Announces Retirement by Year-End Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
3 Reasons to Buy FAS and 3 Reasons Not to
The Direxion Daily Financial Bull 3x Shares ETF aims to triple the S&P Financial Select Sector Index's daily gains -- but its daily losses are amplified, too. It uses total return swaps to deliver those intensified results. It's highly leveraged and exposed to a lot of credit risk. 10 stocks we like better than Direxion Shares ETF Trust - Direxion Daily Financial Bull 3x Shares › The Direxion Daily Financial Bull 3x Shares (NYSEMKT: FAS) exchange-traded fund (ETF) is a leveraged fund that aims to triple the daily performance of the S&P Financial Select Sector index. That index includes 73 of the top financial stocks from the S&P 500, including JPMorgan, Berkshire Hathaway, Visa, Mastercard, Bank of America, and Wells Fargo. FAS uses total swap return agreements with banks to boost its returns. For example, if FAS wants to invest $100 million in the index, it finds a bank to provide it with "synthetic" exposure to $300 million through a short-term loan. The bank then invests $300 million in the index, agrees to pay FAS triple its daily gain, but collects interest from FAS until the swap ends. Simply put, FAS takes on a lot of leverage in pursuit of its goal to triple the index's gains. But that also means it triples the index's losses on down days. A given swap contract with a bank might last for weeks, months, or years, but its gains or losses aren't cumulative and actually "reset" every day. To offset those costs, the fund charges investors a relatively high net expense ratio of 0.89% and parks a lot of its excess cash in U.S. Treasuries. Should investors buy FAS in hopes of tripling the financial sector's returns? Let's review three arguments in favor of buying FAS -- and three reasons to avoid it. It might be smart to invest in FAS for three reasons. First, if the financial sector performs well, the ETF could generate market-beating gains. President Donald Trump has been pressing the Federal Reserve to lower its benchmark interest rates. If it does, that could strengthen banks by sparking more borrowing activity. Meanwhile, the Federal Reserve's recent proposal to free up $6 trillion in its balance sheet capacity could drive more U.S. banks to ramp up their investments in U.S. Treasuries. Second, FAS could be used as a hedge against other bearish bets. For example, if you're shorting individual financial stocks or investing in an ETF that bets against the sector, an FAS holding might offset your losses if those stocks rally instead. Lastly, it does the hard work of bundling multiple messy swaps and other derivatives into a single investment. Buying a single ETF that explains what it is doing in basic terms is much easier for retail investors interested in this sort of investing activity to manage and understand. However, FAS has three glaring weaknesses. First, it can't and won't actually triple the Financial Select Sector index's gains over the long term because it resets its gains and losses daily while constantly paying interest on its swap contracts. Over the past three years, FAS' price rose by 137% as the Financial Select Sector index advanced 60%. More than doubling the index's returns is certainly impressive, but it could quickly give up those gains during a protracted market downturn because the same design that amplifies its gains would similarly triple its losses. Second, its heavy dependence on swap contracts exposes it to a lot of credit risk. If its counterparty bank fails, it loses its leveraged exposure to the index, and it might still owe interest payments on the original contract. Its liquidity -- both on the investor side and the counterparty side -- could also dry up in another credit crunch or market crash. Lastly, FAS is highly sensitive to interest rates. If inflation or geopolitical conflicts result in interest rates staying higher for longer than expected, borrowing and lending activity could slow and banks could struggle -- and the ETF would have to pay higher financing costs on its swap contracts. FAS certainly would not be a good investment for conservative, risk-averse, or passive long-term investors. But if you expect interest rates to decline, the financial sector to heat up, and understand the risks it's taking to "triple" its index's daily gains, then it might be a worthwhile investment -- at least until the next recession. Before you buy stock in Direxion Shares ETF Trust - Direxion Daily Financial Bull 3x Shares, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Direxion Shares ETF Trust - Direxion Daily Financial Bull 3x Shares wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $713,547!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $966,931!* Now, it's worth noting Stock Advisor's total average return is 1,062% — a market-crushing outperformance compared to 177% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 23, 2025 Bank of America is an advertising partner of Motley Fool Money. JPMorgan Chase is an advertising partner of Motley Fool Money. Wells Fargo is an advertising partner of Motley Fool Money. Leo Sun has positions in Berkshire Hathaway. The Motley Fool has positions in and recommends Bank of America, Berkshire Hathaway, JPMorgan Chase, Mastercard, and Visa. The Motley Fool has a disclosure policy. 3 Reasons to Buy FAS and 3 Reasons Not to was originally published by The Motley Fool Sign in to access your portfolio
